1 Min Read
Oct 19 (Reuters) - Pluristem Therapeutics Inc
* FDA grants Pluristem Orphan Drug Designation for its PLX-R18 cell therapy as treatment for acute radiation syndrome Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.